A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia

Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Enjeti, Anoop K., D’Crus, Angel, Melville, Kathleen, Verrills, Nicole M., Rowlings, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881728/
https://www.ncbi.nlm.nih.gov/pubmed/26967515
http://dx.doi.org/10.1097/CAD.0000000000000358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881728/
https://www.ncbi.nlm.nih.gov/pubmed/26967515
http://dx.doi.org/10.1097/CAD.0000000000000358

Ejemplares similares